1-(5-乙基-2,4-二羟基苯基)乙酮 | 4460-42-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(5-乙基-2,4-二羟基苯基)乙酮
• 英文名称: 1-(5-ethyl-2,4-dihydroxyphenyl)ethanone
• 英文别名: 1-(5-ethyl-2,4-dihydroxyphenyl)ethan-1-one；2,4-dihydroxy-5-ethyl-acetophenone；2,4-Dihydroxy-5-ethylacetophenon
• CAS: 4460-42-8
• 化学式: C₁₀H₁₂O₃
• 分子量: 180.203
• InChiKey: XXDREGOVCGEMBJ-UHFFFAOYSA-N

物化性质

• 熔点：
  118–119°C

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2914501900

反应信息

• 作为反应物：
  描述：

  1-(5-乙基-2,4-二羟基苯基)乙酮 在 叠氮基三甲基硅烷 、 potassium carbonate 、 tetra-n-butylammoniumfluoride trihydrate 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 、 丁酮 为溶剂， 反应 50.0h， 生成 1-[5-乙基-2-羟基-4-[[6-甲基-6-(1H-四唑-5-基)庚基]氧基]苯基]乙酮
  参考文献：
  名称：

  Discovery and SAR study of hydroxyacetophenone derivatives as potent, non-steroidal farnesoid X receptor (FXR) antagonists

  摘要：

  Compound 1 (IC50 = 35.2 +/- 7.2 mu M), a moderate FXR antagonist was discovered via high-throughput screening. Structure-activity relationship studies indicated that the shape and the lipophilicity of the substituents of the aromatic ring affect the activity dramatically, increasing the shape and the lipophilicity of the substituents of the aromatic ring enhances the potency of FXR antagonists. Especially, when the OH at C2 position of the aromatic ring was replaced by the OBn substituent (analog 2b), its activity could be improved to IC50 = 1.1 +/- 0.1 mu M. Besides, the length of the linker and the tetrazole structure are essential for retaining the activity. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.01.032
• 作为产物：
  描述：

  4-乙基间苯二酚 在 溶剂黄146 、 zinc(II) chloride 作用下， 生成 1-(5-乙基-2,4-二羟基苯基)乙酮
  参考文献：
  名称：

  Weiss; Kratz, Monatshefte fur Chemie, 1929, vol. 51, p. 391

  摘要：

  DOI：

文献信息

• Leukotriene B.sub.4 antagonists
  申请人：Eli Lilly and Company

  公开号：US05324743A1

  公开（公告）日：1994-06-28

  This invention provides certain 1,2,4,5 substituted benzene derivatives containing "acid" substituents derived from cyclic or heterocyclic moieties. These unique compounds are leukotriene B.sub.4 antagonists and formulations of these derivatives, and a method of using these derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.

  这项发明提供了含有来自环状或杂环基团的“酸”取代基的某些1,2,4,5取代苯衍生物。这些独特化合物是白三烯B.sub.4拮抗剂，以及这些衍生物的配方，以及使用这些衍生物治疗由白三烯过度释放引起的疾病的方法。
• Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
  申请人：——

  公开号：US20030003049A1

  公开（公告）日：2003-01-02

  The present invention provides novel diagnostic compositions comprising a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, diagnostic kits comprising such compositions, and methods of concurrent imaging in a mammal comprising administering a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, and concurrently detecting the radiolabeled LTB4 binding agent bound at the LTB4 receptor and the radiolabeled perfusion imaging agent.

  本发明提供了包括放射标记的LTB4结合剂和放射标记的灌注成像剂的新型诊断组合物，包括这种组合物的诊断试剂盒，以及在哺乳动物中进行同时成像的方法，包括给予放射标记的LTB4结合剂和放射标记的灌注成像剂，并同时检测结合在LTB4受体上的放射标记的LTB4结合剂和放射标记的灌注成像剂。
• Radiopharmaceuticals for imaging infection and inflammation
  申请人：——

  公开号：US20030124053A1

  公开（公告）日：2003-07-03

  The present invention provides novel radiopharmaceuticals useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis. The radiopharmaceuticals bind in vivo to the leukotriene B4 (LTB4) receptor on the surface of leukocytes which accumulate at the site of infection and inflammation. The reagents provided by this invention are also useful for the treatment of diseases associated with infection and inflammation.

  本发明提供了用于诊断感染和炎症的新型放射性药物，用于制备这些放射性药物的试剂和工具包，用于在患者体内成像感染和/或炎症部位的方法，以及用于诊断需要此类诊断的患者中与感染或炎症相关的疾病的方法。这些放射性药物在体内与在感染和炎症部位聚集的白细胞表面的白三烯B4（LTB4）受体结合。本发明提供的试剂还可用于治疗与感染和炎症相关的疾病。
• LTB4 antagonists and radiopharmaceuticals for imaging infection and inflammation
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1293214A3

  公开（公告）日：2003-03-26

  The present invention provides novel radiopharmaceutials useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis. The radiopharmaceuticals bind in vivo to the leukotriene B4 (LTB4) receptor on the surface of leukocytes which accumulate at the site of infection and inflammation. The reagents provided by this invention are also useful for the treatment of diseases associated with infection and inflammation.

  本发明提供了用于诊断感染和炎症的新型放射性药物，用于制备放射性药物的试剂和试剂盒，用于在患者体内成像感染和/或炎症部位的方法，以及用于诊断需要此类诊断的患者中与感染或炎症相关的疾病的方法。这些放射性药物在体内与在感染和炎症部位积聚的白细胞表面的白三烯B4（LTB4）受体结合。本发明提供的试剂还可用于治疗与感染和炎症相关的疾病。
• Synthesis of 6<i>H</i>-Benzo[<i>c</i>]chromenes via Palladium-Catalyzed Intramolecular Dehydrogenative Coupling of Two Aryl C–H Bonds
  作者：Dong-Dong Guo、Bin Li、Da-Yu Wang、Ya-Ru Gao、Shi-Huan Guo、Gao-Fei Pan、Yong-Qiang Wang

  DOI：10.1021/acs.orglett.6b03763

  日期：2017.2.17

  features broad substrate scope and good tolerance of functional groups and uses molecular oxygen as the terminal oxidant. The high efficiency of the approach is verified by concise total synthesis of natural product cannabinol.

  首次报道了钯催化的两个简单的芳烃分子内CH-H / CH-H偶联反应，生成6 H-苯并[ c ]苯并二甲基苯。该方法具有广泛的底物范围和对官能团的良好耐受性，并使用分子氧作为末端氧化剂。天然产物大麻酚的简明全合成证明了该方法的高效率。